Redhill Biopharma
RDHL
38 hedge funds and large institutions have $59.1M invested in Redhill Biopharma in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
45% more capital invested
Capital invested by funds: $40.7M → $59.1M (+$18.4M)
27% more funds holding
Funds holding: 30 → 38 (+8)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$12.9M |
| 2 |
Millennium Management
New York
|
+$1.24M |
| 3 |
Renaissance Technologies
New York
|
+$1.13M |
| 4 |
MC
Menta Capital
San Francisco,
California
|
+$701K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$334K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.28M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$521K |
| 3 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$212K |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$156K |
| 5 |
CBU
CIBC Bank USA
Chicago,
Illinois
|
-$65.2K |
RDHL Hedge Fund Activity: Q3 2018 in Review
38 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q3 2018, worth a combined $59.1M — up 45% from $40.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RDHL positions and 5 closed out — a net gain of 8 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $12.9M. The largest seller was OrbiMed, cutting an estimated $2.28M.
- 38 institutional investors held Redhill Biopharma (RDHL) as of Q3 2018, up from 30 in Q2 2018.
- Funds reported $59.1M of Redhill Biopharma stock for Q3 2018, up 45% quarter-over-quarter.
- 13 funds opened new Redhill Biopharma positions in Q3 2018 and 5 closed out, a net change of +8 holders.
- The largest Redhill Biopharma buyer in Q3 2018 was 683 Capital Management, an estimated $12.9M added.
- The largest Redhill Biopharma seller in Q3 2018 was OrbiMed, an estimated $2.28M sold.
Based on aggregated 13F filings for Q3 2018.